CCAAT/enhancer binding proteins (C/EBPs) are expressed by osteoblasts and adipocytes during differentiation. C/EBPb is critical for adipogenesis; however, its role in osteoblastogenesis is unclear, and its function in the postnatal skeleton is not known. To study C/EBPb in osteoblasts in vivo, we created transgenic mice expressing full length C/EBPb under the control of a 3 . 8 kb fragment of the human osteocalcin promoter. Two transgenic lines were established in a friend leukemia virus strain B genetic background, and compared with wild type littermate controls. Both C/EBPb transgenic lines exhibited osteopenia, with a 30% decrease in bone volume, due to a decrease in trabecular number. The number of osteoblasts and osteoclasts per bone perimeter was not changed. Bone marrow stromal cells from C/EBPb transgenics showed reduced mineralization, and reduced alkaline phosphatase mRNA levels. Calvarial osteoblasts from C/EBPb transgenics displayed reduced alkaline phosphatase activity. To determine the consequences of the Cebpb deletion in vivo, the phenotype of Cebpb null mice was compared with that of wild type controls of identical genetic composition. Cebpb null mice exhibited reduced weight, body fat, and bone mineral density, and decreased bone volume, due to a decrease in trabecular number. The number of osteoblasts and osteoclasts per bone perimeter was not changed. C/EBPb downregulation by RNA interference in calvarial osteoblasts had no effect on osteoblast differentiation/function. The phenotype of the Cebpb inactivation may be secondary to systemic indirect effects, and to direct effects of C/EBPb in osteoblasts. In conclusion, C/EBPb plays a role in mesenchymal cell differentiation and its misexpression in vivo causes osteopenia.
Introduction
CCAAT/enhancer binding proteins (C/EBPs) are a family of transcription factors that play a role in cell proliferation, differentiation, and apoptosis (Nerlov 2007) . Six members of the C/EBP family have been characterized and are termed a, b, d, g, 3, and z, which is also known as C/EBP homologous protein (CHOP) (Ramji & Foka 2002) . C/EBP proteins contain a highly conserved leucine-zipper DNA-binding domain (DBD) and a leucine dimerization domain that enables the formation of homo-and hetero-dimers, which bind to similar DNA sequence motifs. C/EBPs act as regulators of gene expression either by direct DNA binding or by interacting with other transcription factors, including peroxisome proliferator-activated receptor-g2, retinoic acid receptor a, runt-related transcription factor-2 (Runx-2), and nuclear factor of activated T-cells (Clarke et al. 1997 , Gutierrez et al. 2002 , Yang & Chow 2003 , Nerlov 2007 . C/EBPs are expressed in multiple cell types, including osteoblasts and adipocytes, and C/EBPb and d are required for adipogenesis (Rosen et al. 2000 , Pereira et al. 2002 , Hata et al. 2005 , Wiper-Bergeron et al. 2007 ).
C/EBPb exists in three different isoforms, which are translated from different initiation sites within the same mRNA. All three isoforms share the same DNA-binding domain; however, differences in the length of the amino terminal end, determine different functions (Calkhoven et al. 2000) . The full length isoform, termed as liver-enriched activating protein* or LAP*, consists of 296 amino acids and acts as a transcriptional activator, it is commonly referred to as C/EBPb. A second isoform, termed LAP, lacks the first 21 amino acids present in the amino terminal end of full length LAP*, and it is generated from a different translation start site. LAP and LAP* are functionally identical. A third isoform, termed as liver-enriched inhibitory protein (LIP), consists of 144 amino acids and acts as a dominant negative inhibitor of both LAP* and LAP, since it lacks transactivating activity but retains the ability to bind DNA and to dimerize with the other C/EBPb isoforms ( Fig. 1 ; Nerlov 2007) . The function of C/EBPb is regulated by acetylation and phosphorylation at specific residues (Tang et al. 2005 , Cesena et al. 2007 , Li et al. 2007 ). Acetylation at Lys-39 of murine C/EBPb is necessary to activate the transcription of C-fos and Cebpa, whereas sequential phosphorylation is required for the acquisition of C/EBPb DNA binding activity and transactivation of target genes, such as Cebpa and activating protein 2 during adipogenesis in vitro (Cesena et al. 2007 , Li et al. 2007 .
Cebpb null mutant mice are viable, possibly because of partial rescue from other members of the C/EBP family, or because C/EBPb is dispensable during development. Cebpb null mice are affected by a lymphoproliferative disorder, imbalanced lymphocyte helper response, and impaired lipid metabolism in brown fat tissue leading to defective thermoregulation (Screpanti et al. 1995 , Tanaka et al. 1997 . Cebpb null mice exhibit impaired regenerative capacity of hepatocytes, impaired liver function (Greenbaum et al. 1998 , Croniger et al. 2001 , and decreased levels of systemic insulinlike growth factor (IGF) I (Staiger et al. 2008) .
Mesenchymal cells are multipotent cells that can differentiate into cells of various lineages, including osteoblasts, adipocytes, and chondrocytes (Bianco & Gehron 2000) . The fate of mesenchymal cells and their differentiation toward cells of the osteoblastic lineage is controlled by a network of intracellular and extracellular signals, and C/EBPb regulates the commitment of cells of the osteoblastic and adipocytic lineage , Hata et al. 2005 , Winslow et al. 2006 , Franceschi et al. 2007 . Although the role of C/EBPb in adipocyte differentiation is well known, its effects on osteoblastogenesis are less clear (Rosen et al. 2000) . Previous studies from our laboratory have shown that cortisol inhibits osteoblastogenesis and induces the expression of adipocytic markers, which are associated with an increase in C/EBPb expression in ST-2 stromal cells (Pereira et al. 2002) . C/EBPb represses Runx-2 transcription and osteoblastic differentiation of MC3T3 cells; however, C/EBPb interacts with Runx-2 to induce osteocalcin expression (Gutierrez et al. 2002 , Iyer et al. 2004 , Hata et al. 2005 , Wiper-Bergeron et al. 2007 .
The intent of this study was to define the function of C/EBPb in skeletal tissue in vivo. For this purpose, we created transgenic mice overexpressing C/EBPb under the control of a 3 . 8 kb (kb) fragment of the osteoblast specific human osteocalcin promoter, and determined their body composition and skeletal phenotype. Cebpb null mice were also studied, and their body composition and skeletal phenotype determined.
Materials and methods

Generation of transgenic mice and cebpb null mice
After introduction of an optimal Kozak consensus sequence upstream of the translation initiation codon, an 890 bp (bp) fragment, coding for full length murine C/EBPb or LAP* (S L McKnight, Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA), was cloned downstream of a 182 bp artificial intron and a 3 . 8 kb fragment of the human osteocalcin promoter (E Gardiner, University of Queensland, Brisbane, Australia), and upstream of polyadenylation sequences and a 3 . 5 kb fragment of the 3 0 untranslated region and flanking DNA of the Osteocalcin gene ( Fig. 1 ; Cao et al. 1991 , Sims et al. 1997 . Nucleotide sequence analysis confirmed the absence of mutations and correct orientation of the construct. Microinjection of linearized DNA into pronuclei of fertilized oocytes from FVB (for tropism to friend leukemia virus strain B (FVB)) inbred mice, and transfer of microinjected fertilized eggs into pseudopregnant FVB mice were carried out at the transgenic facility of the University of Connecticut Health Center (Farmington, CT, USA). Positive founders were identified by Southern blot analysis of tail DNA (Irwin 1989) . Founder mice were bred to wild type FVB mice to generate transgenic lines, and their phenotype was examined.
To study the effects of the Cebpb deletion in vivo, Cebpb null heterozygous mice (Cebpb C/K ) (S Akira, Osaka University, Osaka, Japan) were re-derived in a C57BL/6 background, and backcrossed five times to obtain a uniform genetic background (Tanaka et al. 1995) . Cebpb null homozygous mice (Cebpb K/K ) were obtained by intermating Cebpb C/K mice, and their phenotype was examined. All animal experiments were approved by the Animal Care and Use Committee of Saint Francis Hospital and Medical Center.
X-ray analysis, bone mineral density, and body composition Radiography was either performed in C/EBPb transgenic and wild type littermate controls or in Cebpb K/K mice and, age and sex, matched wild type controls of the same genetic composition. The mice were anesthetized with tribromoethanol (Sigma-Aldrich), and the X-rays were performed at an intensity of 30 kw for 20 s on a Faxitron X-ray system (model MX 20, Faxitron X-Ray Corp., Wheeling, IL, USA). Total bone mineral density (BMD) (g/cm 2 ) and total body fat (g) were measured on anesthetized mice using the PIXImus small animal DEXA system (GE Medical System/LUNAR, Madison, WI, USA; Nagy et al. 2001) . Calibrations were performed with a phantom of defined value, and quality assurance measurements were performed before each use. The coefficient of variation for total BMD is less than 1% (nZ9).
Bone histomorphometric analysis
Static and dynamic histomorphometry was carried out on transgenic mice and wild type littermate controls and Cebpb K/K mice and wild type, sex and age, matched controls of the same genetic composition. Mice were injected with calcein, 20 mg/kg, and demeclocycline, 50 mg/kg, at an interval of 2 days for 1 and 1 . 5 month old animals and 7 days for 3-month old animals. The mice were killed by CO 2 inhalation 2 days after the demeclocycline injection. Longitudinal sections, 5 mm thick, were cut on a microtome (Microm, Richards-Allan Scientific, Kalamazoo, MI, USA) and stained with 0 . 1% toluidine blue or von Kossa. Static parameters of bone formation and resorption were measured in a defined area between 181 and 1080 mm from the growth plate, using an OsteoMeasure morphometry system (Osteometrics, Atlanta, GA, USA; Gazzerro et al. 2005) . Osteoclasts were identified as multinucleated cells on the trabecular surface and their identity confirmed by the expression of tartrate resistant acid phosphatase determined by histochemical analysis of selected cells, using a commercial kit according to manufacturer's instructions (Sigma-Aldrich). For dynamic histomorphometry, mineralizing surface per bone surface and mineral apposition rate were measured on unstained sections under u.v. light, using a B-2A set long pass filter, and bone formation rate (BFR) was calculated. The terminology and units used are those recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research (Parfitt et al. 1987 ).
Serum C-terminal cross-linked telopeptide of type I collagen
The bone remodeling marker cross-linked telopeptide of type I collagen (CTX) was measured in serum by ELISA using RatLaps ELISA kits (Nordic Bioscience Diagnostics, Herlev, Denmark), according to manufacturer's instructions.
Cell cultures
1-month old C/EBPb heterozygous transgenic and wild type littermate controls from both sexes were killed by CO 2 asphyxiation, the femurs were aseptically removed and used to recover bone marrow stromal cells by centrifugation as described . Cells were plated at a density of 5!10 5 cells/cm 2 and cultured in minimum essential medium (a-MEM, Invitrogen) containing 15% fetal bovine serum (FBS, Atlanta Biologicals, Norcross, GA, USA) at 37 8C in a humidified 5% CO 2 incubator. Confluent cells were switched to a-MEM containing 10% FBS in the presence of 100 mg/ml ascorbic acid and 5 mM b-glycerophosphate and cultured up to 2 weeks to assess changes in mineralized nodule formation and gene expression.
Osteoblasts were isolated from parietal bones of 3-to 5-day old C/EBPb heterozygous transgenic and wild type control littermates from both sexes, by sequential collagenase digestions, as previously described (McCarthy et al. 1990 ). Cells were cultured in DMEM (Invitrogen) supplemented with non-essential amino acids, 20 mM HEPES, 100 mg/ml ascorbic acid, and 10% FBS. Osteoblasts were cultured to 70% confluence and trypsinized; these first passage cells were used for subsequent experiments. Cells were cultured for up to 10 days after confluence, in the presence of 100 mg/ml ascorbic acid and 5 mM b-glycerophosphate (Sigma-Aldrich) to assess changes in gene expression, and treated with bone morphogenetic protein-2 (BMP-2, Wyeth Research, Collegeville, PA, USA) or control vehicle to determine alkaline phosphatase activity (APA).
RNA interference
To downregulate C/EBPb expression in vitro, a 19-mer double stranded small interfering (si) RNA targeted to the murine C/EBPb mRNA sequence was obtained commercially, and a scrambled 19-mer small interfering RNA (siRNA) with no homology to known mouse or rat sequences was used as a control (Applied Biosystems, Foster City, CA, USA; Elbashir et al. 2001 , Sharp 2001 ). C/EBPb or scrambled siRNA, both at 20 nM, were transfected into sub-confluent primary murine osteoblasts using siLentFect lipid reagent, in accordance with manufacturer's instructions (BioRad). Cells were allowed to recover for 24 h prior to the determination of APA. To ensure adequate C/EBPb downregulation, and to measure mRNA levels of osteoblast markers, total RNA was extracted in parallel cell cultures 96 h after the transfection of siRNAs, and mRNA levels determined by real-time reverse transcription-PCR (RT-PCR).
Cytochemical assays and APA
To determine mineralized nodule formation, bone marrow stromal cells were fixed with 3 . 7% formaldehyde and stained with 2% Alizarin Red (Sigma-Aldrich; DAHL 1952). APA was determined in 0 . 5% Triton X-100 cell extractsby the hydrolysis of p-nitrophenyl phosphate to p-nitrophenolmeasured by spectroscopy at 405 nm after 10 min of incubation at room temperature according to the manufacturer's instructions (Sigma-Aldrich). Data are expressed as picomoles of p-nitrophenol released per min per mg of protein.The total protein content was determined in cell extracts by the DC protein assay, in accordance with manufacturer's instructions (Bio-Rad).
Real time RT-PCR
Total RNA was extracted from cell cultures and mRNA levels determined by real-time RT-PCR (Nazarenko et al. 2002a, b) . For this purpose, 5 mg RNA were reverse-transcribed using SuperScript III Platinum Two-Step qRT-PCR kit 0 primers for ribosomal protein L38 (RPL38), and Platinum Quantitative PCR SuperMix-UDG (Invitrogen) at 60 8C for 45 cycles. Transcript copy number was estimated by comparison with a standard curve constructed using C/EBPb (S.L. McKnight), osteocalcin (J.B. Lian, University of Massachusetts, Worcester, MA USA; Lian et al. 1989) , and alkaline phosphatase (American Type Culture Collection; ATCC, Manassas, VA, USA) cDNAs, corrected for RPL38 copy number (ATCC; Kouadjo et al. 2007 ). Reactions were conducted in a 96-well spectrofluorometric thermal iCycler (Bio-Rad), and fluorescence was monitored during every PCR cycle at the annealing step.
Statistical analysis
Data are expressed as meansGS.E.M. Statistical differences were determined by Student's t-test or ANOVA.
Results
C/EBPb transgenic mice
Two lines of FVB mice overexpressing C/EBPb under the control of the 3 . 8 kb human osteocalcin promoter were established. The transgenic lines expressed 8 and 16 copies of the transgene. Both lines had a similar phenotype and the line !10 4 ), and total body fat (g) were obtained from 1-or 3-month old C/EBPb transgenics and wild type littermate controls using a PIXImus small animal DEXA system. BMD was calculated by dividing the bone mineral content (g)/bone area (cm 2 ), and total fat (g) was measured directly by the instrument. Values are meansGS.E.M. (nZ5-12).
expressing 16 copies of the transgene was characterized in detail. C/EBPb transgenic mice were compared with wild type littermate controls of identical sex, at the age of 1 month, a time of high activity of the osteocalcin promoter, or at the age of 3 months (Frenkel et al. 1997) . In the offspring of C/EBPb heterozygous mice intermatings, the ratio of wild type, C/EBPb heterozygous, and C/EBPb homozygous was 29:60:11 for females and 32:63:5 for males. As a consequence, the number of C/EBPb homozygous mice was limited, and this only allowed a detailed histomorphometric analysis of homozygous female mice. We suspect that the non-Mendelian distribution of the transgenic allele is due to intrauterine lethality, likely because of transgene expression in the central nervous system, where the osteocalcin promoter is also active (Frenkel et al. 1997) . There was no significant difference in weight and total body fat in either 1-or 3-month old C/EBPb transgenic mice, when compared with wild type littermate controls (Table 1) . Contact radiography did not reveal any obvious skeletal abnormality, and there was no difference in BMD between transgenics and controls (Table 1) .
Bone histomorphometric analysis of distal femurs from 1-month old female C/EBPb transgenics revealed a decrease in bone volume/tissue volume, secondary to a reduction in the number of trabeculae (Table 2 , Fig. 2A) . A similar decrease in bone volume was observed in male heterozygous transgenics (Table 3 , Fig. 2B ). The number of osteoblasts per tissue area was decreased in C/EBPb transgenics, possibly due to the decreased bone volume, since the number of osteoblasts per bone perimeter, and osteoblast surface/bone surface were not different from controls (Tables 2 and 3) . Changes in bone volume were not associated with an increase in bone resorption since the number of osteoclasts per bone perimeter and eroded surface were not increased in transgenics when compared with controls (Tables 2 and 3) . A modest decrease in the number of osteoclasts per tissue area was detected in female transgenics (Table 2 ). Serum concentrations of CTX (meansGS.E.M.; nZ3-6) were 26 . 5G3 . 1 ng/ml in female heterozygous C/EBPb transgenic mice and 33 . 3G1.9 ng/ml in wild type littermate controls; 30 . 7G5 . 6 ng/ml in female homozygous transgenics and 32 . 3G4 . 0 ng/ml in wild type littermate controls; and 49 . 4G15 . 5 ng/ml in male heterozygous transgenics and 50 . 4G7 . 4 ng/ml in wild-type littermate controls. The results indicate that C/EBPb overexpression does not affect bone remodeling. There were no substantial differences between female and male phenotypes, and no change in mineral apposition rate (not shown) or BFR (Fig. 2) was detected in C/EBPb transgenics. No significant change in the number of adipocytes per tissue area was observed in either female or male transgenics when compared with wild type littermate controls (Tables 2 and 3 ). This could be expected since C/EBPb transcription was directed by the osteocalcin promoter, which is not active in adipocytic cells. 
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Bone histomorphometric analysis of distal femurs from 3-month old female C/EBPb heterozygous transgenics revealed a phenotype analogous to that observed at 1 month, and characterized by a decrease in bone volume/tissue volume, due to a reduction in the number of bone trabeculae (Table 4) . BFR and mineral apposition rate were not affected (data not shown). Serum concentrations of CTX (means GS.E.M.; nZ4) were 17 . 8G1 . 9 ng/ml in female heterozygous C/EBPb transgenic mice and 16 . 3G1 . 1 ng/ml in wild-type littermate controls, confirming that C/EBPb overexpression does not affect bone remodeling.
Both transgenic lines studied displayed analogous skeletal phenotypes. In accordance with the line described, 1-month old male C/EBPb heterozygous transgenics, from the line expressing eight copies of the transgene, exhibited a decrease in bone volume. Bone volume/tissue volume was (means GS.E.M.; nZ6-8) 8 . 0G0 . 4% in controls and 5 . 3G0 . 5% in transgenics, P!0 . 05; trabecular number was 7 . 9G0 . 3 mm K1 in controls and 5 . 9G0 . 5 mm K1 in transgenics, P!0 . 05. In summary, C/EBPb transgenics exhibited osteopenia secondary to a decrease in trabecular number without apparent changes in bone formation or bone resorption.
Bone marrow stromal cell and osteoblast cultures
To investigate the impact of C/EBPb on osteoblastic cell function, bone marrow stromal cells from heterozygous transgenic mice and wild type littermate controls were cultured for up to 2 weeks after confluence, under conditions favoring osteoblastogenesis. C/EBPb overexpression was confirmed by real-time RT-PCR, and C/EBPb transcripts were two fold greater in transgenic than in control cells (Fig. 3A) . Alkaline phosphatase mRNA levels were suppressed by about 40% in cells from transgenics, when compared with control cells (Fig. 3A) . Accordingly, mineralization of the culture, tested after 14 days of incubation by alizarin red staining, was reduced in C/EBPb overexpressing cells, confirming an inhibitory effect of C/EBPb on osteoblastic differentiation (Fig. 3B) . Conversely, osteocalcin mRNA levels were increased in C/EBPb overexpressing cells (Fig. 3A) . This may be explained by observations demonstrating that interactions between Runx-2 and C/EBPb can increase osteocalcin expression (Gutierrez et al. 2002 , Hata et al. 2005 .
To confirm that C/EBPb inhibits osteoblast differentiation, calvarial osteoblasts were harvested from heterozygous transgenic mice and wild-type littermate controls, and cultured for up to 10 days in differentiating conditions. C/EBPb overexpression was confirmed by real-time RT-PCR, and C/EBPb transcripts at confluence were 1.5-fold greater in transgenic than in control cells (Fig. 3C) . Alkaline phosphatase mRNA levels were suppressed by about 50% in cells from transgenics when compared with control cells (Fig. 3C) . Accordingly, calvarial osteoblasts overexpressing C/EBPb exhibited decreased levels of APA when compared with control cells cultured with vehicle or BMP-2 (Fig. 3D) . Osteocalcin transcript levels did not change in osteoblasts from transgenics when compared with control cells (not shown), possibly because the inhibition of differentiated osteoblast function precluded the stimulatory effect of C/EBPb and Runx-2 on osteocalcin transcription in mature osteoblasts.
Cebpb null mice (Cebpb K/K ) Cebpb C/K mice were intermated to obtain Cebpb K/K mice, and their phenotype was examined. The homozygous Cebpb deletion causes female infertility, not allowing the establishment of a Cebpb K/K colony, and limiting the availability of mice for subsequent studies (Sterneck et al. 1997) . Male Cebpb K/K mice showed a tendency towards a reduced body weight and total body fat as compared with wild type age matched controls of identical genetic composition at 1 . 5 and 3 months. The difference in weight and body fat was statistically significant at 6 months of age ( Fig. 4A and B) . Contact radiography of male Cebpb K/K mice did not reveal obvious skeletal abnormalities (data not shown). However, male Cebpb K/K mice at 1 . 5, 3, and 6 months displayed a tendency toward a decrease in BMD, which was statistically significant at 1 . 5 months of age (Fig. 4C) . Male Cebpb K/K mice at 1 . 5, 3, and 6 months exhibited decreased trabecular bone volume that was statistically significant at 3 months of age (Fig. 4D) . A complete histomorphometric analysis, performed in 3-month old Cebpb K/K male mice, revealed a 30% decrease in bone volume/tissue volume, when compared with wild type age matched controls of the same genetic composition (Table 5, Fig. 5 ). The decrease was secondary to a reduced number of trabeculae. Cebpb K/K male mice did not exhibit differences in the number of osteoblasts per bone perimeter and osteoblast surface/bone surface. Similarly, there were no significant changes in the number of osteoclasts/perimeter or in eroded surface in Cebpb null mice, when compared with wild type controls. There was no change in the number of adipocytes per tissue area possibly because C/EBPd alone is sufficient to support adipogenesis (Table 5 ; Lane et al. 1999) . No changes in mineral apposition rate (not shown) and BFR (Fig. 5) were detected. In summary, Cebpb null mice are osteopenic due to a decrease in trabecular number, but do not exhibit changes in bone formation or bone resorption. 
Downregulation of C/EBPb
Skeletal cells from Cebpb K/K mice were not readily available because of the low fertility of Cebpb C/K mice and infertility of Cebpb K/K mice. To investigate the function of C/EBPb, its mRNA levels were downregulated by RNA interference (RNAi) in primary calvarial osteoblasts. C/EBPb downregulation was confirmed by real-time RT-PCR, and C/EBPb transcripts were reduced by 70% in cells transfected with the C/EBPb siRNA, when compared with control cells transfected with scrambled siRNA (Table 6 ). There were no changes in alkaline phosphatase or osteocalcin mRNA levels, measured by real-time RT-PCR, in C/EBPb downregulated cells (Table 6 ). Accordingly, there was no effect on APA in cells transfected with C/EBPb siRNA when compared with control cells (Table 6 ). These results indicate that C/EBPb may be dispensable for osteoblast differentiation in vitro, and suggest that the osteopenic phenotype of the null mutation could be secondary to indirect mechanisms.
Discussion
This report demonstrates that transgenic mice overexpressing C/EBPb under the control of the 3 . 8 kb human osteocalcin promoter exhibit osteopenia. The osteopenia was secondary to a reduced number of trabeculae, but C/EBPb transgenics exhibited no change in osteoblast number or BFR.
The osteopenic phenotype could not be attributed to changes in bone resorption, since, osteoclast number, eroded surface, and biochemical markers of bone remodeling were not different between transgenics and controls. The reduced number of trabeculae could be the result of impaired trabecular formation during skeletal development. This is possible since the osteocalcin promoter is expressed by mature osteoblasts as early as day 18 of embryonic life (Frendo et al. 1998 , Kalajzic et al. 2002 , and C/EBPb overexpression can suppress the terminal differentiation of osteoblasts (Iyer et al. 2004) . A possible explanation for a developmental impact of C/EBPb could be a suppression of Runx-2 transcription, and as a consequence, impaired trabecular bone formation (Otto et al. 1997 , Wiper-Bergeron et al. 2007 . It is possible that osteoblastic differentiation and function are more sensitive to transcriptional changes during development, or that compensatory mechanisms are established postnatally, since osteoblast number and bone formation were not affected in 1-month old C/EBPb transgenics.
Cebpb null mice showed reduced weight, total body fat, and total BMD. Although they were osteopenic, no changes in osteoblast or osteoclast number or BFR were observed. The osteopenic phenotype of Cebpb null mice is in accordance with recent reports from other investigators (Staiger et al. 2008 , Tominaga et al. 2008 , and with a function of C/EBPb in the early differentiation stages of mesenchymal cells, resulting in impaired chondrocyte and osteoblast maturation. This leads to impaired cartilage and bone development, and would explain the reduced number of trabeculae and osteopenic phenotype (Tominaga et al. 2008) . However, other factors probably contribute to the bone loss caused by the Cebpb deletion, since C/EBPb regulates gene expression in a variety of organs (Ramji & Foka 2002) . Cebpb null mice have decreased serum levels of insulin like growth factor I (IGF-I), secondary to decreased IGF-I expression by the liver (Staiger et al. 2008) , and systemic IGF-I plays an important role in skeletal homeostasis (Gazzerro & Canalis 2006 , Yakar et al. Figure 5 Representative histological sections and calcein/demeclocycline labels (upper panels) of bone femoral sections from 3-month old Cebpb null mice and wild-type littermate controls stained with von Kossa without counter stain (final magnification 40! and 100!) or unstained and examined under fluorescence microscopy (final magnification 100!). In the lower panels, bars represent bone volume/tissue volume (BV/TV, %), and BFR/bone surface (BFR/BS, mm 2006, Giustina et al. 2008) . Other contributing factors to the osteopenic phenotype could be the consequences of lymphoproliferative and myeloproliferative alterations, and increased Interleukin-6 serum levels exhibited in the Cebpb null state (Screpanti et al. 1995) . Uncontrolled proliferation of lymphocytes or myeloid precursors can lead to osteopenia (Roodman 1997) , and overexpression of Interleukin-6 in vivo causes impaired growth plate development, increased bone resorption, and decreased osteoblastic differentiation (De et al. 2006) . A systemic nature of the osteopenic phenotype, as opposed to an osteoblast specific effect, is supported by the absence of a cellular phenotype following the downregulation of C/EBPb by RNAi in osteoblasts. However, the absence of a cellular phenotype is in contrast with recently reported findings in osteoblasts from Cebpb null mutants, where inactivation of Cebpb resulted in impaired osteoblast maturation (Tominaga et al. 2008) . The discrepancy between our results and those of Tominaga et al., could be attributed to the transient and possibly incomplete downregulation of C/EBPb by RNAi, causing sufficient C/EBPb expression to support osteoblast differentiation/function for the period of study. It is also possible that under the experimental conditions used in the present work, the levels of C/EBPb were sufficient to maintain osteocalcin expression (Gutierrez et al. 2002) . C/EBPb can favor the early stages of osteoblast differentiation through its hetero-dimerization with activating transcription factor (ATF) 4, and by enhancing the association of ATF 4 with Runx-2 to regulate osteocalcin transcription (Hata et al. 2005 , Tominaga et al. 2008 .
Interactions of C/EBPb with ATF 4 may affect other steps of osteoblastic differentiation, since ATF 4 plays an essential role in this process (Yang et al. 2004) , and could also explain the findings reported in Cebpb null osteoblasts and in the Cebpb null mice. Evidence for direct activity of C/EBPb in osteoblasts also can be derived from observations in vivo. Transgenics overexpressing either LIP, a physiological dominant negative form of C/EBPb (Harrison et al. 2005) , or CHOP, a member of the C/EBP family, are osteopenic (Pereira et al. 2007) . The primary partner of CHOP is C/EBPb and the osteopenia observed in CHOP transgenics is likely secondary to its dimerization with C/EBPb and a decrease in C/EBPb transactivating activity in the skeletal environment (Ron & Habener 1992 , Vinson et al. 2002 . It is of interest that inactivation of Chop causes decreased bone formation, but not an obvious osteopenic phenotype. The function of CHOP, like that of C/EBPb, appears to be dependent on cell type, stage of mesenchymal/osteoblastic cell differentiation, and experimental conditions (Pereira & Delany 2004 , Pereira et al. 2006 , Shirakawa et al. 2006 .
To understand the mechanism leading to the osteopenic phenotype resulting from C/EBPb overexpression, we examined primary osteoblasts and bone marrow stromal cells harvested from C/EBPb transgenic mice. The cellular phenotype is in accordance with the osteopenic phenotype observed, and with previous work demonstrating that the stable transduction of C/EBPb in MC3T3 and C3H10T1/2 cells, by repressing Runx-2 transcription, abrogates osteoblast differentiation induced by retinoic acid (Wiper-Bergeron et al. 2007) . Accordingly, osteoblastic cells from C/EBPb transgenics exhibited reduced mineralization, APA, and alkaline phosphatase mRNA expression. By contrast, transduction of cells of the osteoblastic lineage with adenoviral vectors expressing C/EBPb resulted in enhanced osteoblastic differentiation (Hata et al. 2005) , also suggesting that experimental conditions can have a significant impact on the effect of C/EBPs in osteoblasts. C/EBPb/ATF 4/Runx-2 interactions enhance osteocalcin transcription, and osteocalcin transcripts are increased in conditions of C/EBPb overexpression (Gutierrez et al. 2002 , Tominaga et al. 2008 . Accordingly, osteocalcin mRNA levels were increased in bone marrow stromal cell cultures from C/EBPb transgenics. However, they were not changed in calvarial osteoblasts, possibly due to the inhibitory effect of C/EBPb on Runx-2 expression and on terminal osteoblast differentiation (Iyer et al. 2004 , Wiper-Bergeron et al. 2007 .
C/EBPb is involved in cell-fate decisions and regulates the balance between osteoblasts and adipocytes in vitro, and the Cebpb deletion in vivo impairs the formation of white and brown adipose tissue (Tanaka et al. 1997 , Hata et al. 2005 . Accordingly, male Cebpb null mice exhibited reduced total body fat. The Cebpb deletion did not affect the number of bone marrow adipocytes, possibly because C/EBPd is sufficient to sustain adipogenesis in the absence of C/EBPb (Lane et al. 1999) . However, the effect of the Cebpb deletion on the differentiation of bone marrow adipocytes in vivo is not known, and it is conceivable that genes regulating the development of brown and white adipose tissue could be different from genes regulating bone marrow adipogenesis. We did not detect an effect on total body fat or in the number of adipocytes in C/EBPb transgenics. This should be expected, since C/EBPb was expressed under the control of the osteocalcin promoter, which is expressed by mature osteoblasts and not by undifferentiated mesenchymal cells capable of adipocytic differentiation.
In conclusion, C/EBPb plays an important regulatory role in osteoblast differentiation and skeletal function in vivo. 
